Compare NGS & VALN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | NGS | VALN |
|---|---|---|
| Founded | 1998 | 2012 |
| Country | United States | France |
| Employees | N/A | N/A |
| Industry | Oilfield Services/Equipment | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 473.6M | 495.5M |
| IPO Year | 2006 | 2021 |
| Metric | NGS | VALN |
|---|---|---|
| Price | $35.61 | $7.08 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 2 |
| Target Price | ★ $40.67 | $15.50 |
| AVG Volume (30 Days) | ★ 95.8K | 83.9K |
| Earning Date | 05-11-2026 | 05-07-2026 |
| Dividend Yield | ★ 1.08% | N/A |
| EPS Growth | ★ 14.60 | N/A |
| EPS | ★ 0.83 | N/A |
| Revenue | ★ $172,315,000.00 | N/A |
| Revenue This Year | $15.05 | N/A |
| Revenue Next Year | $9.52 | $93.87 |
| P/E Ratio | $43.25 | ★ N/A |
| Revenue Growth | ★ 9.94 | N/A |
| 52 Week Low | $25.53 | $4.75 |
| 52 Week High | $44.61 | $12.23 |
| Indicator | NGS | VALN |
|---|---|---|
| Relative Strength Index (RSI) | 47.26 | 68.58 |
| Support Level | $34.45 | $5.10 |
| Resistance Level | $39.56 | $7.31 |
| Average True Range (ATR) | 1.16 | 0.23 |
| MACD | 0.12 | 0.00 |
| Stochastic Oscillator | 40.13 | 80.20 |
Natural Gas Services Group Inc provides natural gas compression equipment and services to the energy industry. The company manufactures, fabricates, rents, sells, and maintains natural gas compressors and flare systems for oil and natural gas production and plant facilities. Its operating units include Rental, Sales, and Aftermarket services. It operates in one reporting segment. The company generates the majority of its revenue by renting out low- to medium-horsepower compression equipment to natural gas production companies in unconventional oil and gas regions of the United States.
Valneva SE is a vaccine company focused on developing life-saving vaccines. Its portfolio includes three vaccines for travelers. The segments of the group are Commercialized vaccines which relate to marketed vaccines, the group's vaccines IXIARO/JESPECT, DUKORAL, IXCHIQ; Covid includes development, manufacturing, & distribution related to the COVID-19 vaccine, Vaccine candidates which relate to research and development programs to generate new approvable products to generate future cash flows from product sales through partnering with pharmaceutical companies; & Technologies and services which relate to services and inventions at a commercialization stage. The company generates majority of its revenue from product sales.